E-GUIDE Cell-Based Off-Target Detection

E-GUIDE Cell-Based Off-Target Detection

1. Background

From basic science to clinical application, gene-editing technology is redefining the boundaries of medicine at an unprecedented pace. In this revolutionary process, off-target effect assessment has become a critical bottleneck between scientific breakthroughs and clinical translation. Researchers require precise off-target data to reveal editing mechanisms and guide the development of next-generation high-fidelity tools; pharmaceutical R&D teams rely on comprehensive off-target analysis to evaluate candidate products and determine whether they can cross the clinical threshold; regulatory agencies regard off-target assessment as an insurmountable barrier to ensuring patient safety. These multidimensional needs are driving the rapid development of highly sensitive, unbiased off-target detection methods.

The FDA, in its guidance document Human Gene Therapy Products Incorporating Human Genome Editing (2024), explicitly requires comprehensive off-target risk assessment for gene-editing products, emphasizing the adoption of multiple methods for genome-wide analysis to reduce potential bias in off-target site identification. Among these, the FDA specifically highlights "cellular-based assays" — experimental methods based on cellular systems that can detect off-target sites of editing tools in a real cellular environment. Similarly, China's Center for Drug Evaluation (CDE), in the Technical Guidelines for Pharmacological Research and Evaluation of In Vivo Gene Therapy Products (Trial) (2022), aligns with the FDA in requiring multi-method identification of off-target events.

Figure 1. FDA and CDE guidance requirements for off-target detection

Under this regulatory landscape, E-GUIDE has emerged as the gold standard for cell-based off-target detection owing to its high sensitivity for identifying off-target sites in living cells. To ensure technical reliability and accuracy, ZhuHai GeneRulor has conducted comprehensive method validation in strict accordance with ICH Q2(R2) guidelines and the FDA Guidance for Industry on Analytical Procedures and Methods Validation for Drugs and Biologics, establishing a complete technical evaluation framework. ZhuHai GeneRulor has successfully provided gene-editing safety evaluation services compliant with regulatory standards to numerous domestic and international gene therapy companies, fully supporting IND submissions and clinical translation.

2. Detection Principle

E-GUIDE is a highly efficient genome-wide off-target detection method. Its fundamental principle involves the use of short double-stranded oligodeoxynucleotide tags (dsODN tags) to label CRISPR-Cas-induced DSB sites (both on-target and off-target), followed by high-throughput sequencing of the genomic regions flanking the tag insertion sites, and final bioinformatic analysis to determine the precise genomic location and functional annotation of off-target sites.

The E-GUIDE experimental workflow is as follows:

(1) Cell transfection: co-transfect Cas9/sgRNA plasmid (or RNP/mRNA) together with dsODN into target cells;

(2) DNA double-strand break repair: at CRISPR-Cas9-generated DSB sites, dsODN is integrated into the break site via the Non-Homologous End Joining (NHEJ) pathway;

(3) Genomic DNA extraction: isolate genomic DNA from the processed cells;

(4) DNA fragmentation and end repair: sonicate the extracted DNA into fragments and perform end-blunting;

(5) Adapter ligation: ligate specific adapters to both ends of the DNA fragments;

(6) PCR amplification: perform two rounds of PCR amplification using dsODN-specific primers and adapter-specific primers to enrich for dsODN-containing fragments;

(7) High-throughput sequencing: perform paired-end sequencing on the amplified products;

(8) Bioinformatics analysis.

Figure 2. Schematic illustration of the E-GUIDE off-target detection principle

3. Detection and Analytical Advantages of E-GUIDE

3.1 Comprehensive Capture of DSB Sites Induced by Gene Editing

(1) Precise cut site identification: the unique integration characteristics of dsODN enable accurate identification of cleavage sites, achieving single-nucleotide-resolution analysis;

(2) Genome-wide unbiased off-target detection: independent of bioinformatic predictions, capable of discovering novel, previously unreported off-target sites;

(3) Low-frequency off-target event capture: high sensitivity enabling detection of off-target events at frequencies as low as 0.001%, significantly superior to other methods.

3.2 Outstanding Analytical Performance

ZhuHai GeneRulor rigorously follows international experimental standards, conducting systematic validation of E-GUIDE technology across four critical performance dimensions:

3.3 Service Advantages

(1) Comprehensive method validation: E-GUIDE has undergone systematic validation with rigorous quality control standards established at key workflow steps including dsODN integration, PCR amplification, and UMI barcoding; the detection workflow strictly adheres to ICH Q2(R2) and FDA bioanalytical method validation guidelines, ensuring detection results comply with domestic and international regulatory standards;

(2) Leading technology platform: proprietary UMI molecular barcode technology effectively eliminates PCR duplication and sequencing errors, significantly improving data accuracy and ensuring the reliability of off-target site identification;

(3) Full-panel off-target site annotation: comprehensive multi-dimensional annotation information provided for off-target sites, including chromosomal position, gene region, relationship to genes, and cancer-gene association, enabling comprehensive assessment of off-target risk;

(4) Rich success case portfolio: E-GUIDE off-target detection services have been successfully delivered to numerous gene therapy companies, supporting smooth IND submissions;

(5) Customized analytical solutions: customized detection schemes based on target site characteristics and editing system (Cas9/Cas12 and others);

(6) Full-process service model: end-to-end gene-editing safety solutions encompassing target site design evaluation, sample testing, and IND submission data support.

4. Application Scenarios

(1) Target site screening-stage off-target risk assessment: genome-wide qualitative identification of off-target sites to help research teams screen for the target site with the lowest off-target risk;

(2) sgRNA design optimization: comparison of off-target profiles across different sgRNAs to select the sequence design with the highest specificity and to reduce potential off-target risk;

(3) Basic research tool: a tool for investigating the specificity mechanisms of the CRISPR-Cas system, supporting the improvement and optimization of gene-editing technologies;

(4) Preclinical safety evaluation: meeting regulatory agency requirements for rigorous off-target detection of gene-editing therapeutics to provide key safety data for translational research;

(5) IND submission data support: provision of cell-based, genome-wide level off-target detection reports compliant with CDE and FDA requirements, supporting the clinical IND submission of gene-editing therapeutics.

5. Case Analysis

The E-GUIDE analytical reports provided by ZhuHai GeneRulor adopt a standardized format to ensure professional and comprehensive data presentation. The introductory section covers project background, experimental rationale, E-GUIDE technical principles, library construction workflow description, and bioinformatics analysis pipeline overview, providing clients with the necessary technical context. This is followed by sample information and sequencing data statistics, which include sample metadata, raw sequencing data quality metrics, and control group alignment result statistics, ensuring data quality and reliability. In addition, the report includes the following key components:

(1) On-Target/Off-Target Site Basic Information: This table presents the basic information analysis of on-target and off-target sites for the sample. Rows are sorted in descending order of sequencing read count, with each row representing a specific chromosomal position. It records the chromosome number, precise genomic coordinates, total read count, and detailed read type breakdown (forward reads, reverse reads, forward ODN insertion reads, reverse ODN insertion reads), effectively displaying the basic information of each on-target and potential off-target site in the sample.

Figure 3. E-GUIDE representative report (off-target site basic information)

(2) Off-Target Site Safety Analysis: The report provides detailed off-target analysis information from the gene-editing experiment, including sample name, chromosomal number, off-target site start coordinates, affected genes and their distance information, gene region classification type (e.g., intergenic region, intronic), and whether cancer-associated genes are involved and other key data.

Figure 4. E-GUIDE representative report (off-target site detailed annotation)

(3) Off-Target Site Visualization: The report provides the sgRNA sequence alignment status and off-target analysis for each gene-editing system in the sample. The top portion of the figure displays the reference sgRNA sequence; below it are the alignment results of each potential off-target site with that sequence. Each row represents one off-target site; color-coded markers indicate aligned bases; dots (.) represent bases identical to the sgRNA sequence; letters represent mismatched bases. The figure also includes the read count, mismatch count, permissible bulge mismatch count, and chromosomal coordinate information for each site. The visualization enables a direct presentation of the directional precision and off-target profile of the gene-editing tool, while simultaneously evaluating on-target efficiency and potential off-target risk.

Figure 5. E-GUIDE representative report (off-target site visualization).

6. Service Content

* Service turnaround: standard workflow 20–30 business days.

* Service highlight: integrated end-to-end service support from sgRNA design through final data analysis is available.

7. Sample Requirements

* Notes: (1) All samples must meet the above standards to ensure the accuracy and reliability of detection results. (2) Clients may also submit tissue or cell pellet samples for DNA extraction; tissue requirement: >50 mg; cell pellet requirement: >2×10⁵ cells per site. (3) For special sample types, please contact the ZhuHai GeneRulor technical team in advance (Tel: 400-6309596; Order/Technical Support: service@generulor.com).

8. References

[1] International Council for Harmonisation. ICH Q2(R2): Guideline on Validation ofAnalytical Procedures. 2023.

[2] U.S. Food and Drug Administration. Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry [EB/OL]. Silver Spring, MD: FDA, January 2024.

[3] Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33(2):187-197.

[4] Kim D, Kim S, Kim S, Park J, Kim JS. Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq. Genome Res. 2016;26(3):406-415.

[5] Hu J, Meyers RM, Dong J, Panchakshari RA, Alt FW, et al. Detecting DNA double-stranded breaks in mammalian genomes by linear amplification-mediated high-throughput genome-wide translocation sequencing. Nat Protoc. 2016;11(5):853-871.

[6] Lee CM, Cradick TJ, Fine EJ, Bao G. Nuclease target site selection for maximizing on-target activity and minimizing off-target effects in genome editing. Mol Ther. 2016;24(3):475-487.

[7] Kleinstiver BP, Tsai SQ, Prew MS, et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat Biotechnol. 2016;34(8):869-874.

[8] Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490-495.